Evidence map›Paper›PMID 32242356›Full record

ArticleThe New England journal of medicine2020

Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.

John A Jernigan, Kelly M Hatfield, Hannah Wolford, Richard E Nelson, Babatunde Olubajo, Sujan C Reddy, Natalie McCarthy, Prabasaj Paul, L Clifford McDonald, Alex Kallen and 3 more

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 307 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
307citing papers in PubMed, 1 pooled it
26.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05824689 terminatednot on this mapstarted 2022, after this paper: background citation

Exploratory Study of Fluoroquinolone Resistance for Patients Undergoing Autologous Hematopoietic Stem Cell (HSC) Transplantation in the Treatment of Multiple Myeloma

TypeobservationalSponsorHackensack Meridian HealthRan2022 to 2025Enrolled124ConditionsMultiple Myeloma
NCT06272994 nacompletednot on this mapstarted 2024, after this paper: background citation

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc)

TypeinterventionalSponsorVanderbilt University Medical CenterRan2024 to 2025Enrolled277ConditionsCommunity-acquired PneumoniaArmsMRSA Nasal Swab PCR
3 · Its place in the literature

Who cites it

307 citing papers in PubMed, 1 synthesis or guideline pooled it, 559 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Electronic Clinical Quality Measures of Antibiotic Use in Hospitalized Adults With Uncomplicated Community-Acquired Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  9. Evaluation of Changes inOpen forum infectious diseases · 2026
    Article
  10. Pathogens (Basel, Switzerland) · 2026
    Article
  11. Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026
    Review
  12. Applicability of Nanopore-only whole-genome sequencing forJournal of clinical microbiology · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Is Preoperative Antimicrobial Prophylaxis Necessary in Testicular Torsion Surgery? Results from the National Surgical Quality Improvement Program Pediatric.European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie · 2026
    Article
  18. Article
  19. Review
  20. Article

247 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

John A JerniganFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Kelly M HatfieldFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Hannah WolfordFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Richard E NelsonFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Babatunde OlubajoFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Sujan C ReddyFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Natalie McCarthyFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Prabasaj PaulFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
L Clifford McDonaldFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Alex KallenFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Anthony FioreFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Michael CraigFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
James BaggsFrom the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
University of Utah · US

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundMultidrug-resistant (MDR) bacteria that are commonly associated with health care cause a substantial health burden. Updated national estimates for this group of pathogens are needed to inform public health action.

methodsUsing data from patients hospitalized in a cohort of 890 U.S. hospitals during the period 2012-2017, we generated national case counts for both hospital-onset and community-onset infections caused by methicillin-resistant

resultsThe hospital cohort in the study accounted for 41.6 million hospitalizations (>20% of U.S. hospitalizations annually). The overall rate of clinical cultures was 292 cultures per 1000 patient-days and was stable throughout the time period. In 2017, these pathogens caused an estimated 622,390 infections (95% confidence interval [CI], 579,125 to 665,655) among hospitalized patients. Of these infections, 517,818 (83%) had their onset in the community, and 104,572 (17%) had their onset in the hospital. MRSA and ESBL infections accounted for the majority of the infections (52% and 32%, respectively). Between 2012 and 2017, the incidence decreased for MRSA infection (from 114.18 to 93.68 cases per 10,000 hospitalizations), VRE infection (from 24.15 to 15.76 per 10,000), carbapenem-resistant acinetobacter species infection (from 3.33 to 2.47 per 10,000), and MDR

conclusionsHealth care-associated antimicrobial resistance places a substantial burden on patients in the United States. Further work is needed to identify improved interventions for both the inpatient and outpatient settings. (Funded by the Centers for Disease Control and Prevention.).

Indexed as

Drug Resistance, Multiple, BacterialAcinetobacterAdolescentAdultAgedBacterial InfectionsCarbapenemsCephalosporin ResistanceChildChild, PreschoolCommunity-Acquired InfectionsCross InfectionEnterobacteriaceaeHealth SurveysHospitalizationHumansCarbapenems

Identifiers

PMID32242356
PMCPMC10961699
OpenAlexW3014508302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.